Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ATACSeq - human CAR-T cells treated with lenalidomide

ABSTRACT: Genome-wide DNA accessibility maps of chromatin state in human CAR-T cells treated with lenalidomide in the presense or absense of Ag-specific restimulation

ORGANISM(S): Homo sapiens

PROVIDER: GSE113853 | GEO | 2019/07/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

RNASeq: lenalidomide-treated anti-BCMA CAR T cells

Project description:Transcriptom-wide RNA expression profilng in human CAR-T cells treated with lenalidomide in the presense or absense of Ag-specific restimulation

2019-07-16 | GSE113281 | GEO

ATACSeq - human CAR-T cells treated with lenalidomide

Project description:ATACSeq - human CAR-T cells treated with lenalidomide

| PRJNA454267 | ENA

RNASeq: lenalidomide-treated anti-BCMA CAR T cells

Project description:RNASeq: lenalidomide-treated anti-BCMA CAR T cells

| PRJNA450645 | ENA

Effects of lenalidomide treatment on CAR-redirected T cells derived from CLL patients

Project description:Significant response rates have been reported in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphomas (DLBCL), mantle cell lymphomas and follicular lymphomas. In contrast, in CTL019 trials, only 26% of CLL patients had durable antitumor responses with dramatic mechanisms of resistance to anti-CD19.CAR T-cell therapy. Low expression of programmed cell death protein 1 (PD1) has been identified as pre-treatment predictor of response in these trials, though the mechanisms responsible for a limited efficacy in CLL remain poorly understood. Additional studies have demonstrated that CD8+ anti-CAR T cells from patients with CLL exhibit impaired metabolic function compared to CD8+ T cells from healthy donors and that these features are associated with T-cell exhaustion and a reduction in T-cell activation and degranulation. Several T-cell defects have been observed in patients with CLL and are mainly related to impaired immune synapse (IS) formation, and these defects could ultimately impact on the CAR T-cell activation and expansion upon antigen encounter. Thus, the purpose of this study was to explore the possibility of using lenalidomide, an immunomodulatory agent that has induced significant, long-lasting responses in CLL patients, to enhance the therapeutic efficacy of CD23.CAR-redirected T cells.

2022-02-28 | GSE178893 | GEO

Root tip: WT vs. rss3 and -NaCl vs. +NaCl

Project description:Transcriptional profiling of WT and rss3 root tips, grown in the presense or absense of 100 mM NaCl for 3 days.

2012-10-15 | GSE41442 | GEO

Effects of lenalidomide treatment on CAR-redirected T cells derived from CLL patients

Project description:Effects of lenalidomide treatment on CAR-redirected T cells derived from CLL patients

| PRJNA741468 | ENA

Nanostring analysis of human SUV39H1-knockout CAR T compared to control CAR T cells (mock) at different timepoint

Project description:Failure of adoptive T cell therapies in cancer patients is linked to limited T cell expansion and persistence, even in memory-prone 41BB-(BBz)-based chimeric antigen receptor (CAR) T cells. In murine CD8+ T cells, SUV39H1 promotes differentiation and expansion of effector CD8+ T cells during acute infection by Listeria monocytogenes by silencing stemness and memory genes (Pace et al. Science, 2018). The purpuse of this study is to investigate the transcriptomic differences of SUV39H1 knock-out versus mock human 41BBz-CAR T cells by Nanostring at different cycles of restimulation.

2023-10-31 | GSE244030 | GEO

Root tip: WT vs. rss3 and -NaCl vs. +NaCl

Project description:Transcriptional profiling of WT and rss3 root tips, grown in the presense or absense of 100 mM NaCl for 3 days. WT (-NaCl), WT (+NaCl), rss3 (-NaCl), rss3 (+NaCl). Three biological replicates.

2012-10-15 | E-GEOD-41442 | biostudies-arrayexpress

Effect of Lenalidomide on human macrophages.

Project description:Lenalidomide, an IMiD® immunomodulatory agent used for the treatment of multiple myeloma (MM),is believed to target the stromal support, but its precise mechanism on the phenotype or the effector functions of macrophages is still unclear. To investigate the effect of lenalidomide on macrophages, M-CSF generated macrophages were treated with Lenalidomide and analyzed by RNA-seq.

2021-01-23 | GSE165332 | GEO

Expression data of human NK cell treated with lenalidomide

Project description:Lenalidomide, an analogue of thalidomide, is immuno-modulatory drug and has been used for many types of cancer therapy. Recently, it has been reported that lenalidomide can enhance the function of NK cell during IL-2 response. However, molecular mechanism of action of lenalidomide in NK cells is unclear still. To investigate the modification by lenalidomide on NK cells, we conducted the analysis of gene expression on NK cells.

2022-10-14 | GSE138850 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data